Following approval from an EGM, Norway-based Serodus is to merge with the Danish peptide specialist company, Phlogo. The merger will accelerate Serodus' commercialisation and development strategy with the addition of two first-in-class drug candidates from Phlogo: SER130, an interleukin (IL)-4 partial receptor agonist for acute myocardial infarction (MI) and SER140, an IL-1 receptor antagonist for Type II diabetes.
SER130 and SER140 have been developed by researchers at Copenhagen University who have been concentrating on mimicking and inhibiting endogenous inflammatory cascades. SER130 improves Serodus' portfolio in its core cardiovascular therapeutic drug development field by focusing on the severe tissue damage which occurs after MI. SER140 is also an anti-inflammatory drug candidate, but targeted at diabetes, which is outside Serodus' main focus. The company plans to seek a partner to continue development of this product.